HC Wainwright Has Positive Outlook of RYTM FY2025 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Rhythm Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($3.10) per share for the year, up from their prior estimate of ($3.13). HC Wainwright has a “Buy” rating and a $125.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q4 2025 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.98) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.10). Rhythm Pharmaceuticals had a negative net margin of 110.32% and a negative return on equity of 433.21%. The business had revenue of $51.30 million during the quarter, compared to analysts’ expectations of $50.71 million.

Several other brokerages have also issued reports on RYTM. TD Cowen reiterated a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. Guggenheim lifted their price objective on Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research note on Wednesday, October 8th. Wells Fargo & Company raised their target price on Rhythm Pharmaceuticals from $129.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Oppenheimer cut Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $131.29.

Rhythm Pharmaceuticals Stock Performance

NASDAQ:RYTM opened at $103.12 on Thursday. The company has a fifty day moving average of $106.50 and a two-hundred day moving average of $101.09. The stock has a market capitalization of $6.88 billion, a PE ratio of -33.26 and a beta of 2.00. Rhythm Pharmaceuticals has a fifty-two week low of $45.90 and a fifty-two week high of $122.20.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. boosted its holdings in Rhythm Pharmaceuticals by 2.2% in the 3rd quarter. RA Capital Management L.P. now owns 5,681,359 shares of the company’s stock valued at $573,760,000 after purchasing an additional 120,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Rhythm Pharmaceuticals by 39.2% in the third quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock valued at $504,589,000 after acquiring an additional 1,407,313 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Rhythm Pharmaceuticals by 2.5% in the third quarter. Federated Hermes Inc. now owns 1,727,885 shares of the company’s stock valued at $174,499,000 after acquiring an additional 41,391 shares during the last quarter. Westfield Capital Management Co. LP grew its position in Rhythm Pharmaceuticals by 21.5% in the second quarter. Westfield Capital Management Co. LP now owns 1,629,468 shares of the company’s stock worth $102,966,000 after acquiring an additional 288,376 shares during the period. Finally, Geode Capital Management LLC increased its stake in Rhythm Pharmaceuticals by 1.9% during the second quarter. Geode Capital Management LLC now owns 1,311,253 shares of the company’s stock worth $82,868,000 after acquiring an additional 24,085 shares during the last quarter.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 3,350 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the sale, the insider directly owned 20,814 shares of the company’s stock, valued at $2,310,354. This trade represents a 13.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joseph Shulman sold 9,748 shares of Rhythm Pharmaceuticals stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $115.24, for a total value of $1,123,359.52. Following the transaction, the insider owned 8,509 shares in the company, valued at approximately $980,577.16. This represents a 53.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 15,913 shares of company stock valued at $1,818,963 over the last 90 days. Company insiders own 6.10% of the company’s stock.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.